IceCure Expands Breast Cancer Cryoablation Study with Legacy Health Site

  • IceCure Medical adds Legacy Health in Portland, OR as a new U.S. clinical site for its ChoICE Study evaluating ProSense® cryoablation for low-risk breast cancer.
  • The study, approved by the FDA, aims to enroll 400 patients across up to 30 clinical sites in the U.S.
  • Nathalie Johnson, M.D., FACS, Senior Medical Director of Legacy Cancer Institute, will provide clinical leadership for the site.
  • The ChoICE Study is designed to generate additional real-world clinical data on ProSense® as a minimally invasive alternative to surgery.

IceCure's expansion of the ChoICE Study with Legacy Health underscores the growing interest in minimally invasive alternatives to surgery for low-risk breast cancer. The study's focus on real-world clinical data aligns with broader industry trends toward personalized and less invasive cancer treatments. The inclusion of a nationally recognized breast cancer expert like Dr. Nathalie Johnson bolsters the study's credibility and potential impact on clinical practice.

Study Execution
Whether IceCure can maintain momentum in patient enrollment across the expanded clinical network.
Regulatory Impact
How the additional real-world data from the ChoICE Study may influence future FDA decisions on ProSense®.
Market Adoption
The pace at which cryoablation gains acceptance as a standard treatment option for low-risk breast cancer.